Company News »

Sarepta Therapeutics to Announce First Quarter 2015 Financial Results and Recent Corporate Developments on May 7, 2015

Business Wire
Share on StockTwits
Published on

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) , a developer of innovative RNA-targeted therapeutics, will report first quarter 2015 financial results before the NASDAQ Global Market opens on Thursday, May 7, 2015. Subsequently, at 8:00 a.m., Eastern Time, Edward Kaye, M.D., Sarepta’s interim chief executive officer and chief medical officer, and Sandy Mahatme, Sarepta’s chief financial officer, will host a conference call to discuss first quarter financial results and to provide a corporate update.

The conference call may be accessed by dialing 866-436-9172 for domestic callers and 630-691-2760 for international callers. The passcode for the call is 39538738. Please specify to the operator that you would like to join the “Sarepta First Quarter 2015 Earnings Call.” The conference call will be webcast live under the investor relations section of Sarepta’s website at and will be archived there following the call for 90 days. Please connect to Sarepta’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta Therapeutics is focused on developing first-in-class RNA-targeted therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company’s diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world’s most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-targeted science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at

Internet Posting of Information

We routinely post information that may be important to investors in the ‘For Investors’ section of our web site at We encourage investors and potential investors to consult our website regularly for important information about us.

Share on StockTwits